Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor

Molecular and Cellular Endocrinology

Volumn 399, Issue , 2015, Pages 259-266

  Eeles, Damien G ^a,b   Hodge, Jason M ^c,d   Singh, Preetinder P ^a   Schuijers, Johannes A ^b   Grills, Brian L ^b   Gillespie, Matthew T ^a,e   Myers, Damian E ^f   Quinn, Julian M W ^a,e  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c GEELONG HOSPITAL   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

Author keywords

Bone resorption; Interleukin; Osteoclast; Th2 cytokine

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 33; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; ACID PHOSPHATASE; DIFFERENTIATION ANTIGEN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-33, MOUSE; ISOENZYME; NFATC1 PROTEIN, HUMAN; NFATC1 PROTEIN, MOUSE; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFSF11 PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; BONE MARROW PROGENITOR CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; NORMAL HUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; METABOLISM; PHYSIOLOGY; STEM CELL;

ACID PHOSPHATASE; ANIMALS; ANTIGENS, DIFFERENTIATION; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; HUMANS; INTERLEUKINS; ISOENZYMES; MICE; MONOCYTES; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84910070143     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.10.014     Document Type: Article

References (35)

1. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13(18):2412-2424.
2. Edwards J.R., Sun S.G., Locklin R., Shipman C.M., Adamopoulos I.E., Athanasou N.A., et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006, 54(5):1451-1462.
3. Elleder M. Enzyme patterns in human endocytotic multinucleate giant cells - a histochemical study. Acta Histochem 1986, 79(1):1-10.
4. Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med 1998, 188(5):997-1001.
5. Gooi J.H., Chia L.Y., Walsh N.C., Karsdal M.A., Quinn J.M., Martin T.J., et al. Decline in calcitonin receptor expression in osteocytes with age. J. Endocrinol 2014, 221(2):181-191.
6. Hattersley G., Chambers T.J. Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. Endocrinology 1989, 124(4):1689-1696.
7. Hayakawa H., Hayakawa M., Kume A., Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem 2007, 282(36):26369-26380.
8. Hemingway F., Taylor R., Knowles H.J., Athanasou N.A. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 2011, 48(4):938-944.
9. Hemingway F., Kashima T.G., Knowles H.J., Athanasou N.A. Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT. Exp. Mol. Pathol 2013, 94(2):380-385.
10. Heymann D., Guicheux J., Gouin F., Cottrel M., Daculsi G. Oncostatin M stimulates macrophage-polykaryon formation in long-term human bone-marrow cultures. Cytokine 1998, 10(2):98-109.
11. Hodge J.M., Kirkland M.A., Aitken C.J., Waugh C.M., Myers D.E., Lopez C.M., et al. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J. Bone Miner. Res 2004, 19(2):190-199.
12. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun 1999, 265(1):144-150.
13. Keller J., Catala-Lehnen P., Wintges K., Schulze J., Bickert T., Ito W., et al. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem. Biophys. Res. Commun 2012, 417(1):217-222.
14. Kim K., Kim J.H., Lee J., Jin H.M., Kook H., Kim K.K., et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 2007, 109(8):3253-3259.
15. Liew F.Y. IL-33: a Janus cytokine. Ann. Rheum. Dis 2012, 71(Suppl. 2):i101-i104.
16. Martin T.J., Quinn J.M., Gillespie M.T., Ng K.W., Karsdal M.A., Sims N.A. Mechanisms involved in skeletal anabolic therapies. Ann. N. Y. Acad. Sci 2006, 1068:458-470.
17. Mirosavljevic D., Quinn J.M., Elliottt J., Horwood N.J., Martin T.J., Gillespie M.T. T cells mediate an inhibitory effect of interleukin 4 on osteoclastogenesis. J. Bone Miner. Res 2003, 18:984-993.
18. Mun S.H., Ko N.Y., Kim H.S., Kim J.W., Kim do K., Kim A.R., et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell. Mol. Life Sci 2010, 67(22):3883-3892.
19. Nicholson G.C., Moseley J.M., Sexton P.M., Mendelsohn F.A., Martin T.J. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J. Clin. Invest 1986, 78(2):355-360.
20. Onal M., Xiong J., Chen X., Thostenson J.D., Almeida M., Manolagas S.C., et al. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem 2012, 287(35):29851-29860.
21. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139(10):4424-4427.
22. Quinn J.M., Morfis M., Lam M.H., Elliott J., Kartsogiannis V., Williams E.D., et al. Calcitonin receptor antibodies in the identification of osteoclasts. Bone 1999, 25(1):1-8.
23. Quinn J.M., Itoh K., Udagawa N., Hausler K., Yasuda H., Shima N., et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res 2001, 16(10):1787-1794.
24. Quinn J.M., Whitty G.A., Byrne R.J., Gillespie M.T., Hamilton J.A. The generation of highly enriched osteoclast-lineage cell populations. Bone 2002, 30(1):164-170.
25. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem 2010, 285(33):25103-25108.
26. Saleh H., Eeles D., Hodge J.M., Nicholson G.C., Gu R., Pompolo S., et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 2011, 152(5):1911-1922.
27. Schulze J., Bickert T., Beil F.T., Zaiss M.M., Albers J., Wintges K., et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res 2011, 26(4):704-717.
28. Sinningen K., Tsourdi E., Rauner M., Rachner T.D., Hamann C., Hofbauer L.C. Skeletal and extraskeletal actions of denosumab. Endocrine 2012, 42(1):52-62.
29. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416(6882):744-749.
30. van de Wijngaert F.P., Burger E.H. Demonstration of tartrate-resistant acid phosphatase in un-decalcified, glycolmethacrylate-embedded mouse bone: a possible marker for (pre)osteoclast identification. J. Histochem. Cytochem 1986, 34(10):1317-1323.
31. Yao Z., Xing L., Boyce B.F. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J. Clin. Invest 2009, 119(10):3024-3034.
32. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(7):3597-3602.
33. Zaiss M.M., Kurowska-Stolarska M., Bohm C., Gary R., Scholtysek C., Stolarski B., et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J. Immunol 2011, 186(11):6097-6105.
34. Zhao B., Takami M., Yamada A., Wang X., Koga T., Hu X., et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med 2009, 15(9):1066-1071.
35. Zhao B., Grimes S.N., Li S., Hu X., Ivashkiv L.B. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J. Exp. Med 2012, 209(2):319-334.